

REMARKS

Status of the Claims

Claims 1 to 14 are currently pending. Claims 11 to 14 have been withdrawn from consideration as being directed to a separate invention. Claims 1 to 10, directed to the elected invention, are currently under examination.

Amendments to the Specification

Applicants have amended the specification to correct a typographical error in the SEQ ID NO: 4. SEQ ID NO: 4 is identified to be a domain dimer (*see* specification page 26, line 15). However, inadvertently, the as-filed sequence of the dimer (SEQ ID NO: 4) also includes the sequence of linker (SEQ ID NO: 5). As explained on page 25, line 25 to page 26, line 5, SEQ ID NO: 5 is added to SEQ ID NO: 4 to yield SEQ ID NO: 2. Accordingly, Applicants have amended SEQ ID NO: 4 to delete the linker (SEQ ID NO: 5) and to only recite the dimer. No new matter has been added.

Response to Restriction Requirement

In response to the Restriction Requirement dated August 19, 2009, Applicants hereby elect without traverse Group I, claims 1 to 10, drawn to a support having an affinity for an antibody and a method of using the support.

In addition, the Office Action has also requested an election of following species: (1) a single SEQ ID sequence and (2) a single species of support having an amino group with a defined linker sequence and a single species of amino sequence for R₁. Accordingly, Applicants hereby elect without traverse the following species:

(1) SEQ ID NO: 3; and

(2) Polyarylamine as the support having an amino group with SEQ ID NO: 5 as the defined linker (*i.e.* R₂) and SEQ ID NO: 3 as the amino acid sequence (for R₁).

Conclusion

The foregoing amendments and remarks are being made to place the application in condition for allowance. Applicants respectfully request entry of the amendments, reconsideration, and the timely allowance of the pending claims. A favorable action is awaited. Should an interview be helpful to further prosecution of this application, the Examiner is invited to telephone the undersigned.

Except for issue fees payable under 37 C.F.R. 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. 1.16 and 1.17 which may be required, including any required extension of time fees, or to credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **constructive petition for extension of time** in accordance with 37 C.F.R. 1.136(a)(3).

Dated: **September 21, 2009**
Morgan, Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
202-739-3000

Respectfully submitted,
Morgan, Lewis & Bockius LLP

_____/Sally Teng/
Sally P. Teng
Registration No. 45,397